Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide maintenance versus observation after rituximab-containing induction, high-dose chemotherapy, and autologous stem cell transplantation in first-line mantle cell lymphoma
2009-012807-25Phase 3Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in mantle cell lymphoma (MCL) comparing Lenalidomide maintenance with Observation (2 arms). Primary endpoint: Progression-free survival. Started Feb 2010; status: completed.
02
Drugs
lenalidomide
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2009-012807-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012807-25.